A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes
Public ClinicalTrials.gov record NCT00260065. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Advanced-Stage Myelodysplastic Syndromes
Study identification
- NCT ID
- NCT00260065
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eisai Inc.
- Industry
- Enrollment
- 99 participants
Conditions and interventions
Conditions
Interventions
- Decitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2005
- Primary completion
- May 31, 2008
- Completion
- Nov 30, 2008
- Last update posted
- May 19, 2013
2005 – 2008
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35235 | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Boca Raton | Florida | 33486 | — |
| Not listed | Fort Myers | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | New Port Richey | Florida | 34652 | — |
| Not listed | Griffin | Georgia | 30224 | — |
| Not listed | Chicago | Illinois | 60637-1470 | — |
| Not listed | Maywood | Illinois | 60153 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | Hackensack | New Jersey | 07601 | — |
| Not listed | Buffalo | New York | 14263 | — |
| Not listed | Canton | Ohio | 44718 | — |
| Not listed | Charleston | South Carolina | 29406 | — |
| Not listed | Memphis | Tennessee | 38138 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Midland | Texas | 79701 | — |
| Not listed | Seattle | Washington | 98104 | — |
| Not listed | La Crosse | Wisconsin | 54601 | — |
| Not listed | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00260065, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 19, 2013 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00260065 live on ClinicalTrials.gov.